Pat W. Whitworth
YOU?
Author Swipe
View article: Teaching Methods that Promote Medical Student Attendance: A Scoping Review
Teaching Methods that Promote Medical Student Attendance: A Scoping Review Open
Background Medical student class attendance, especially traditional lectures, is on the decline. As faculty explore a variety of pedagogical approaches, understanding how to encourage attendance and engagement is critical. The purpose of t…
View article: A 7-Gene Biosignature for Ductal Carcinoma in situ of the Breast Identifies Subpopulations of HER2-positive Patients With Distinct Recurrence Rates After Breast-Conserving Surgery and Radiation Therapy
A 7-Gene Biosignature for Ductal Carcinoma in situ of the Breast Identifies Subpopulations of HER2-positive Patients With Distinct Recurrence Rates After Breast-Conserving Surgery and Radiation Therapy Open
The 7-gene biosignature with RRt identified a subset of HER2(3+) patients with greater IBR rates following BCS and RT beyond traditional clinical and pathologic features. Consideration of therapies to reduce these elevated IBR rates should…
View article: Tyrer-Cuzick Lifetime Risk is Not Associated with Non-BRCA1/2 Pathogenic Variants for Breast Carcinoma
Tyrer-Cuzick Lifetime Risk is Not Associated with Non-BRCA1/2 Pathogenic Variants for Breast Carcinoma Open
Purpose: The Tyrer-Cuzick lifetime risk score (TC LR) is used to estimate the probability of an unaffected female patient developing breast cancer as well as their likelihood of carrying a BRCA1/BRCA2 pathogenic variant (PV), considering f…
View article: The Clinical Utility of a 7-Gene Biosignature on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery: An Updated Analysis of the DCISionRT® PREDICT Study
The Clinical Utility of a 7-Gene Biosignature on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery: An Updated Analysis of the DCISionRT® PREDICT Study Open
Background Breast-conserving surgery (BCS) followed by adjuvant radiotherapy (RT) is a standard treatment for ductal carcinoma in situ (DCIS). A low-risk patient subset that does not benefit from RT has not yet been clearly identified. The…
View article: Validation of a clinical breast cancer risk assessment tool combining a polygenic score for all ancestries with traditional risk factors
Validation of a clinical breast cancer risk assessment tool combining a polygenic score for all ancestries with traditional risk factors Open
PurposeWe previously described a combined risk score (CRS) that integrates a multiple-ancestry polygenic risk score (MA-PRS) with the Tyrer-Cuzick (TC) model to assess breast cancer (BC) risk. Here, we present a longitudinal validation of …
View article: Analytical validation of the 7-gene biosignature for prediction of recurrence risk and radiation therapy benefit for breast ductal carcinoma in situ
Analytical validation of the 7-gene biosignature for prediction of recurrence risk and radiation therapy benefit for breast ductal carcinoma in situ Open
Purpose Ductal carcinoma in situ (DCIS), is a noninvasive breast cancer, representing 20-25% of breast cancer diagnoses in the USA. Current treatment options for DCIS include mastectomy or breast-conserving surgery (BCS) with or without ra…
View article: Figure S4 from A Biological Signature for Breast Ductal Carcinoma <i>In Situ</i> to Predict Radiotherapy Benefit and Assess Recurrence Risk
Figure S4 from A Biological Signature for Breast Ductal Carcinoma <i>In Situ</i> to Predict Radiotherapy Benefit and Assess Recurrence Risk Open
Figure S4. Multivariate Analysis of Clinicopathologic and Molecular Factors Excluding Patients with Positive Margins for 10 Year IBE Risk
View article: Table S5 from A Biological Signature for Breast Ductal Carcinoma <i>In Situ</i> to Predict Radiotherapy Benefit and Assess Recurrence Risk
Table S5 from A Biological Signature for Breast Ductal Carcinoma <i>In Situ</i> to Predict Radiotherapy Benefit and Assess Recurrence Risk Open
DS Group Classification within Select Clinicopathologic Factors
View article: Figure S2 from Validation of a Ductal Carcinoma <i>In Situ</i> Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy
Figure S2 from Validation of a Ductal Carcinoma <i>In Situ</i> Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy Open
Association of DS and clinicopathologic factors and treatment with ipsilateral breast event risks, forest plot of a multivariate analysis
View article: Table S6 from A Biological Signature for Breast Ductal Carcinoma <i>In Situ</i> to Predict Radiotherapy Benefit and Assess Recurrence Risk
Table S6 from A Biological Signature for Breast Ductal Carcinoma <i>In Situ</i> to Predict Radiotherapy Benefit and Assess Recurrence Risk Open
Analysis of Linear Model at Selected Thresholds
View article: Figure S3 from A Biological Signature for Breast Ductal Carcinoma <i>In Situ</i> to Predict Radiotherapy Benefit and Assess Recurrence Risk
Figure S3 from A Biological Signature for Breast Ductal Carcinoma <i>In Situ</i> to Predict Radiotherapy Benefit and Assess Recurrence Risk Open
Figure S3. Baseline Risks as a Function of Year of Diagnosis
View article: Supplementary Methods from Validation of a Ductal Carcinoma <i>In Situ</i> Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy
Supplementary Methods from Validation of a Ductal Carcinoma <i>In Situ</i> Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy Open
Supplementary Methods
View article: Table S3 from A Biological Signature for Breast Ductal Carcinoma <i>In Situ</i> to Predict Radiotherapy Benefit and Assess Recurrence Risk
Table S3 from A Biological Signature for Breast Ductal Carcinoma <i>In Situ</i> to Predict Radiotherapy Benefit and Assess Recurrence Risk Open
Clinicopathologic Features by Treatment & Risk Group (margin negative)
View article: Table S3 from Validation of a Ductal Carcinoma <i>In Situ</i> Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy
Table S3 from Validation of a Ductal Carcinoma <i>In Situ</i> Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy Open
10-year total breast event risk for patients treated with radiation therapy and optionally with endocrine therapy compared to those with no endocrine therapy, by DS risk groups
View article: Table S1 from Validation of a Ductal Carcinoma <i>In Situ</i> Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy
Table S1 from Validation of a Ductal Carcinoma <i>In Situ</i> Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy Open
Clinical and pathologic characteristics of evaluable KPNW study subjects compared to non-evaluable KPNW subjects among eligible study cases
View article: Figure S4 from A Biological Signature for Breast Ductal Carcinoma <i>In Situ</i> to Predict Radiotherapy Benefit and Assess Recurrence Risk
Figure S4 from A Biological Signature for Breast Ductal Carcinoma <i>In Situ</i> to Predict Radiotherapy Benefit and Assess Recurrence Risk Open
Figure S4. Multivariate Analysis of Clinicopathologic and Molecular Factors Excluding Patients with Positive Margins for 10 Year IBE Risk
View article: Figure S2 from Validation of a Ductal Carcinoma <i>In Situ</i> Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy
Figure S2 from Validation of a Ductal Carcinoma <i>In Situ</i> Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy Open
Association of DS and clinicopathologic factors and treatment with ipsilateral breast event risks, forest plot of a multivariate analysis
View article: Table S1 from A Biological Signature for Breast Ductal Carcinoma <i>In Situ</i> to Predict Radiotherapy Benefit and Assess Recurrence Risk
Table S1 from A Biological Signature for Breast Ductal Carcinoma <i>In Situ</i> to Predict Radiotherapy Benefit and Assess Recurrence Risk Open
Biomarker Assay Methodology
View article: Data from A Biological Signature for Breast Ductal Carcinoma <i>In Situ</i> to Predict Radiotherapy Benefit and Assess Recurrence Risk
Data from A Biological Signature for Breast Ductal Carcinoma <i>In Situ</i> to Predict Radiotherapy Benefit and Assess Recurrence Risk Open
Purpose:Ductal carcinoma in situ (DCIS) patients and their physicians currently face challenging treatment decisions with limited information about the individual's subsequent breast cancer risk or treatment benefit. The DCISionRT biologic…
View article: Table S2 from A Biological Signature for Breast Ductal Carcinoma <i>In Situ</i> to Predict Radiotherapy Benefit and Assess Recurrence Risk
Table S2 from A Biological Signature for Breast Ductal Carcinoma <i>In Situ</i> to Predict Radiotherapy Benefit and Assess Recurrence Risk Open
Multivariate Cox Proportional Hazards Analysis of DS, RT and Study Site by Risk Groups
View article: Figure S1 from A Biological Signature for Breast Ductal Carcinoma <i>In Situ</i> to Predict Radiotherapy Benefit and Assess Recurrence Risk
Figure S1 from A Biological Signature for Breast Ductal Carcinoma <i>In Situ</i> to Predict Radiotherapy Benefit and Assess Recurrence Risk Open
Figure S1. Study Population Diagram
View article: Table S4 from Validation of a Ductal Carcinoma <i>In Situ</i> Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy
Table S4 from Validation of a Ductal Carcinoma <i>In Situ</i> Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy Open
Multivariable Cox proportional hazard regression analysis of alternative invasive score in relation to invasive breast event outcome, overall and by receipt of radiation therapy
View article: Supplementary Methods from Validation of a Ductal Carcinoma <i>In Situ</i> Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy
Supplementary Methods from Validation of a Ductal Carcinoma <i>In Situ</i> Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy Open
Supplementary Methods
View article: Table S1 from A Biological Signature for Breast Ductal Carcinoma <i>In Situ</i> to Predict Radiotherapy Benefit and Assess Recurrence Risk
Table S1 from A Biological Signature for Breast Ductal Carcinoma <i>In Situ</i> to Predict Radiotherapy Benefit and Assess Recurrence Risk Open
Biomarker Assay Methodology
View article: Table S2 from Validation of a Ductal Carcinoma <i>In Situ</i> Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy
Table S2 from Validation of a Ductal Carcinoma <i>In Situ</i> Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy Open
10-year risks by DS risk group and radiation therapy in evaluable patients with negative margin status